Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287608 · ClinicalTrials.gov registry record
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 50
- Enrollment target
NCT04287608 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT04287608 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.
Interventions
- DRUG dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2023-03-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04287608
The ClinicalTrials.gov registry entry for NCT04287608 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dupilumab is the first listed.
NCT04287608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04287608 about?
NCT04287608 is a clinical study titled "Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis". The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for con...
What is the current status of trial NCT04287608?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2021-03-10. Estimated completion is 2023-03-29.
What interventions are being tested in trial NCT04287608?
The interventions under investigation include: dupilumab (DRUG).
Who is sponsoring clinical trial NCT04287608?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.